TEGLUTIK 5 mg/ml, oral suspension bottle, 300 ml
Active ingredients: Riluzole
Commercialized according to BDPMDispensing in France: Prescription only
Oral suspensionbottle, 300 mlorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- TEGLUTIK 5 mg/ml, suspension buvable
- Pharmaceutical form
- suspension buvable
- Route of administration
- orale
- Presentation description
- 1 flacon(s) en verre jaune(brun) de 300 ml avec fermeture de sécurité avec adaptateur polyéthylène basse densité (PEBD) avec seringue(s) pour administration orale polyéthylène haute densité (PEHD)
- Marketing authorisation holder
- ITALFARMACO (ESPAGNE)
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 5 Apr 2016
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Initial prescription by a specialist
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
68413596CIP72756601CIP133400927566011Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| RILUZOLEsuspension | 5 mg · 1 mL de suspension buvable | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.